Yarema Kristin reported grant involving 137,200 derivative units of ImageneBio, Inc. at $0.00 for $0 on Aug 14, 2026

Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Chief Executive Officer
Chief Executive Officer
Filed Aug 17, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
137,200Employee Stock Option (right to buy)
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
137,200Direct
Trade date
Aug 14, 2026Grant
Filed
Aug 17, 2026, 5:00 PM ET3-day reporting delay
Accession
0001803794-26-000003Code A · Transaction 782
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Aug 14, 2026Grant254,800$0.00$0Trade 781
Aug 14, 2026Grant250,000$0.00$0Trade 783
3 transaction rows in this filing. Joint filers share the same rows.

IMA price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
IMA · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +7.7%1w ago +2%1d ago +5.2%
Returns since7d +0.7%30d −12%90d180d1y

Footnotes in full

F1: Represents the number of shares of the Issuer's Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of Common Stock upon settlement. 25% of RSUs will vest and settle into Common Stock on April 14, 2027, and the remaing RSUs will vest in a series of 12 equal quarterly installments thereafter, subject to the Reporting Person's continuous service with the Issuer through each such vesting date. F2: The options vest over four years, with 25% of the shares vesting on April 14, 2027, and the remaining shares vesting in a series of 36 successive equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer through each such vesting date. F3: The options vest over four years in a series of 48 successive equal monthly installments commencing on May 14, 2026, subject to the Reporting Person's continuous service with the Issuer through each such vesting date.